MedPath

Nuvig Therapeutics, Inc.

Nuvig Therapeutics, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2021-01-01
Employees
11
Market Cap
-
Website
http://www.nuvigtherapeutics.com

Clinical Trials

2

Active:0
Completed:0

Trial Phases

2 Phases

Phase 2:1
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (50.0%)
Phase 2
1 (50.0%)

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

Not Applicable
Recruiting
Conditions
Immune Thrombocytopenia (ITP)
Interventions
First Posted Date
2025-07-31
Last Posted Date
2025-07-31
Lead Sponsor
Nuvig Therapeutics, Inc.
Target Recruit Count
10
Registration Number
NCT07095127
Locations
🇺🇸

Nuvig Site, Westbury, New York, United States

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP

Phase 2
Recruiting
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
First Posted Date
2025-06-18
Last Posted Date
2025-06-18
Lead Sponsor
Nuvig Therapeutics, Inc.
Target Recruit Count
60
Registration Number
NCT07027111
Locations
🇺🇸

Nuvig Site, Denton, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.